DND-41

DND-41是人类急性白血病细胞系，最初是在1977年分离自一名13岁的T型急性淋巴性白血病的男性患者的外周血，具有p53蛋白的突变及CDKN2B（英语：CDKN2B）与CDKN2A（英语：CDKN2A）的缺失^[1]。

科研用途

1985年，有学者测试三尖杉酯堿 (harringtonine) 对十种人类白血病-淋巴廇细胞系的生长抑制作用，发现其对DND-41细胞最不活跃，与抑制最活跃者 (即HL-60细胞) 存在具有70倍的活性差异。进行进一步测试后，发现不同细胞系对三尖杉酯堿的敏感性可能与HT结合的程度有关，以及三尖杉酯堿对细胞的影响基本上取决于暴露的时间，而不是浓度^[2]。2015年，有研究人员发现，在治疗中使用剂量低于人类所能承受的N-乙酰半胱氨酸，会破坏白细胞介素7受体（英语：Interleukin-7 receptor）突变型的DND-41细胞中的IL7R同源二聚体，故而植入至免疫缺陷小鼠体内的DND-41细胞会显著被其抑制，提供有效且可行的治疗策略^[3]。

参考资料

^ Borgonovo Brandter, L; Heyman, M; Rasool, O; Liu, Y; Grandér, D; Einhorn, S. p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines.. European journal of haematology. 1996-05, 56 (5): 313–8 [2019-12-21]. PMID 8641406. doi:10.1111/j.1600-0609.1996.tb00721.x. （原始内容存档于2019-12-21）.
^ Takemura, Y; Ohnuma, T; Chou, TC; Okano, T; Holland, JF. Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells.. Cancer chemotherapy and pharmacology. 1985, 14 (3): 206–10 [2019-12-21]. PMID 3995683. doi:10.1007/bf00258117. （原始内容存档于2019-12-21）.
^ Mansour, MR; Reed, C; Eisenberg, AR; Tseng, JC; Twizere, JC; Daakour, S; Yoda, A; Rodig, SJ; Tal, N; Shochat, C; Berezovskaya, A; DeAngelo, DJ; Sallan, SE; Weinstock, DM; Izraeli, S; Kung, AL; Kentsis, A; Look, AT. Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.. British journal of haematology. 2015-01, 168 (2): 230–8 [2019-12-21]. PMID 25256574. doi:10.1111/bjh.13115. （原始内容存档于2019-12-21）.

外部链接

Cellosaurus entry for DND-41（页面存档备份，存于互联网档案馆）

[1] Borgonovo Brandter, L; Heyman, M; Rasool, O; Liu, Y; Grandér, D; Einhorn, S. p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines.. European journal of haematology. 1996-05, 56 (5): 313–8 [2019-12-21]. PMID 8641406. doi:10.1111/j.1600-0609.1996.tb00721.x. （原始内容存档于2019-12-21）.

[2] Takemura, Y; Ohnuma, T; Chou, TC; Okano, T; Holland, JF. Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells.. Cancer chemotherapy and pharmacology. 1985, 14 (3): 206–10 [2019-12-21]. PMID 3995683. doi:10.1007/bf00258117. （原始内容存档于2019-12-21）.

[3] Mansour, MR; Reed, C; Eisenberg, AR; Tseng, JC; Twizere, JC; Daakour, S; Yoda, A; Rodig, SJ; Tal, N; Shochat, C; Berezovskaya, A; DeAngelo, DJ; Sallan, SE; Weinstock, DM; Izraeli, S; Kung, AL; Kentsis, A; Look, AT. Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.. British journal of haematology. 2015-01, 168 (2): 230–8 [2019-12-21]. PMID 25256574. doi:10.1111/bjh.13115. （原始内容存档于2019-12-21）.

[1]

[2]

[3]